Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
about
Deciphering the role of RND efflux transporters in Burkholderia cenocepaciaThe use of nanoscale visible light-responsive photocatalyst TiO2-Pt for the elimination of soil-borne pathogensHospital epidemiology and infection control in acute-care settings.Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data.Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance.Molecular epidemiology of methicillin-resistant Staphylococcus aureus isolated in serial cultures from the respiratory tract of children with cystic fibrosis.Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosisAntibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungiThe changing microbial epidemiology in cystic fibrosis.Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.National athletic trainers' association position statement: skin diseases.Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosisIncreased congregational support for parents of children with cystic fibrosis.Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Infection control in cystic fibrosis.Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patientsWithin-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients.Isolation of infectious cystic fibrosis patients: results of a systematic review.Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis.Practical management of cystic fibrosis.Molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain.Control of antibiotic-resistant bacteria in the office and clinic.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Molecular approaches to pathogenesis study of Burkholderia cenocepacia, an important cystic fibrosis opportunistic bacterium.Staphylococcus aureus in early cystic fibrosis lung disease.Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.Factors to consider when selecting a nebulizer for a new inhaled drug product development program.How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilmsViruses in cystic fibrosis patients' airways.Comparison of the BBL CHROMagar Staph aureus agar medium to conventional media for detection of Staphylococcus aureus in respiratory samples.Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis.Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivoBurkholderia cepacia complex in Serbian patients with cystic fibrosis: prevalence and molecular epidemiology.Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.Efflux-mediated resistance to a benzothiadiazol derivative effective against Burkholderia cenocepacia.Validation of AKACID plus as a room disinfectant in the hospital setting.Detection of rapidly growing mycobacteria in routine cultures of samples from patients with cystic fibrosis.
P2860
Q28477821-D1410B64-5853-49C8-AC1F-3195C8BA2940Q28481158-75CEA8F9-7E11-4317-8014-7ECF5E6D3DECQ30429049-74690809-D8F9-4507-84B9-1A7F37C5CAA3Q31131422-6AC6106D-FABE-4B8D-94FB-11364F3902E7Q33504396-B18BB38C-78F5-4230-BB09-698C8889A9CDQ33594673-B5C1F57A-767F-4B84-9CE6-58B079B12327Q33785116-BCC2EA28-6404-4689-B42D-89C81D15BBFCQ33792765-7CA196FC-E4E4-4A8A-9FB6-FE928B6E0E93Q33825634-A181C323-766F-41E1-AE79-953CF7F43A4BQ33852394-48E9B66C-210D-4D30-B1C0-337046CED8EAQ33956730-41FF0389-F9A4-4E3C-819C-03911BE4CE59Q33984713-08AF975F-B58E-41AA-B4DB-B273B2FF403CQ34275485-02FAD5AA-3364-4B3C-9286-6BBB35E331C0Q34568983-B46BFD48-3254-4BFC-BC8B-AF1E8CAFDDA1Q35071790-D61ADAE2-46E1-4451-B0BB-5106847444E4Q35127240-579DFF6A-D0E5-4035-A817-4D4214BBB896Q35545544-6FEAF6BB-D488-4B80-8453-56D0711D6E81Q35669548-50AE9DC2-8542-45F7-95E2-43081024842AQ35813781-4728E6BA-0103-4DAF-BB67-C7D4D5AA2498Q36112367-65288054-4FC7-4FCC-B7B6-24BA0CD09B95Q36216240-94BF0838-D5A1-4F6A-B469-52468E415C26Q36568679-FAF2AA62-0FDB-496A-8614-546E9B0B3D72Q36884485-2F169652-5096-4FB8-A60F-269CC3B6990AQ37477929-61776F49-D53E-4DD8-A6A6-5C897430D97EQ37940005-755B8AEC-D909-4494-AD56-14A1C7AAF45FQ37945517-59B32CF4-B9F3-4A2F-BABD-FDB19F081CFAQ38130897-04B80494-7D74-48E0-B219-DCD32660AA4EQ38282581-6E6B94D5-858F-4651-AEAA-C6E335CBACE1Q38373085-39D2C7A0-1D07-42EA-BF83-4272EC098570Q38635041-88599E76-9E89-47DA-802C-62F8B0951A00Q39167799-03B26CD3-BD80-4FD5-B900-A2F4E2BF7957Q39199043-7B1416EA-D726-4E2F-8128-66D61F365295Q39486100-739AF101-38BD-43BD-A5F4-8FD9BD4FB3A1Q40485160-82E2C119-A8E8-45C5-A4DA-CA6C7C8DB79BQ40556314-749D31AF-99CC-4FAF-8D80-E6579DB50DBEQ40675257-DDE375E7-1890-4888-9EB6-E6FA302D7E60Q40704655-A2A82AF0-3E9C-4FF1-81DE-BF885D2983ACQ41036943-012A0F48-8007-4C6C-892E-804BF8200A09Q41478993-1630DB48-F75D-4479-9925-1C186767E841Q41866799-DDC8F146-3434-4C65-9853-880901675791
P2860
Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Infection control recommendati ...... tient-to-patient transmission.
@en
Infection control recommendati ...... tient-to-patient transmission.
@nl
type
label
Infection control recommendati ...... tient-to-patient transmission.
@en
Infection control recommendati ...... tient-to-patient transmission.
@nl
prefLabel
Infection control recommendati ...... tient-to-patient transmission.
@en
Infection control recommendati ...... tient-to-patient transmission.
@nl
P2093
P2860
P356
P1476
Infection control recommendati ...... tient-to-patient transmission.
@en
P2093
Cystic Fibrosis Foundation
Jane Siegel
Lisa Saiman
P2860
P356
10.1086/503485
P433
P577
2003-05-01T00:00:00Z